Ketamine Update with Brandon Kitay, M.D.

episode

Psychiatry & Psychotherapy Podcast not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

Related

recent transcribed audio

NPR News: 09-29-2026 7AM EDT 4 min · 29 Sep 2026 · NPR News Now

7AM ET 09/29/2026 Newscast 3 min · 29 Sep 2026 · Fox News Hourly Update

Most replayed moment: The hidden dangers of hearing loss | Prof. Marcelo Rivolta 8 min · 29 Sep 2026 · ZOE Science & Nutrition

Overmedicated To Death: Former FDA Officer on Presley Gerber & The Psychiatric Crisis in America w/ Dr. Mary Talley Bowden, Dr. Josef Witt-Doerring & Ronald Owens Jr. – Ask Dr. Drew – Ep 670 1h 19m · 29 Sep 2026 · Ask Dr. Drew

Federal boost for Navitas 6 min · 29 Sep 2026 · Wall Street Breakfast

SpaceX Starship Finally Reached Orbit & Why Dudes Are Becoming Cat Dads 29 min · 29 Sep 2026 · Morning Brew Daily

Report any issue

Source

Recorded27 Jan 2022

Publisherpsychiatrypodcast.libsyn.com ↗

Handlerec:5603968

Show notes

Esketamine is the first non-monoaminergic based medication which is FDA approved and indicated for treatment refractory depression. A longer duration of undertreated depression is associated with poor longitudinal functional outcomes. Instead of cycling patients through monoaminergic antidepressant trials and cognitive behavioral therapy approaches, according to Dr. Kitay, providers should consider treatments like esketamine much sooner in the treatment course. By listening to this episode, you can earn 1.25 Psychiatry CME Credits. Link to blog. Link to YouTube video.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Sign in